<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659788</url>
  </required_header>
  <id_info>
    <org_study_id>CoEnzyme Q10-HMO-CTIL</org_study_id>
    <nct_id>NCT01659788</nct_id>
  </id_info>
  <brief_title>Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age</brief_title>
  <official_title>Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the investigators research is to explore energy production of the ovarian
      follicle in older reproductive age women at the time of oocyte retrieval.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of ATP production</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steriodogenesis associated enzymatic activity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian Response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative pregnancy rate per retrieval</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative live birth rate per retrieval</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Co Enzyme Q10 levels in maternal serum by HPLC</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Function at Advanced Reproductive Age</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q10 concomitant treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.
Other name: Ubiquinone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q10 concomitant treatment</intervention_name>
    <arm_group_label>Coenzyme Q10 concomitant treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 38-43 years at the time of enrollment

          -  Diagnosis of primary infertility

        Exclusion Criteria:

          -  Body mass index (BMI) &gt; 30 kg/m2

          -  Early follicular phase (day 2-4) serum FSH level &gt; 20 mIU/ml.

          -  Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography

          -  Any current use of systemic steroid medication or any infertility treatment within 3
             months of study enrollment.

          -  Any contraindication to being pregnant and carrying a pregnancy to term.

          -  Contraindication for the use of CoQ10, or fertility medications.

          -  Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.

          -  Absence of one or two ovaries

          -  Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal
             dysfunction, organic intracranial lesion, polycystic ovarian syndrome,
             hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).

          -  History (within past 12 months) or current abuse of alcohol or drugs.

          -  Administration of any investigational drugs within three months prior to study
             enrollment.

          -  Any medical condition that may interfere with the absorption, distribution, metabolism
             or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes
             and liver dysfunction

          -  Unexplained gynecological bleeding.

          -  Ejaculated sperm is not sufficient for ICSI

          -  Patient not able to communicate adequately with the investigators and to comply with
             the requirements of the entire study.

          -  Abnormal COH screening blood done for both partners, including: prolactin, thyroid
             stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and
             screen and syphilis serology prior to participation in study.

          -  Unwillingness to give written informed consent. Previous entry into this study or
             simultaneous participation in another clinical trial.

          -  The concurrent use of any of the following drugs:

          -  Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol,
             atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil,
             tricyclic antidepressant medications (including amitriptyline, amoxapine,
             clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and
             trimipramine) multivitamins or any vitamin supplementation except Folic acid.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronit Kochman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronit Kochman, MD</last_name>
    <phone>00 972 50 8946414</phone>
    <email>kochman@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadas Lamberg, PhD</last_name>
      <phone>00 972 2 677572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2012</study_first_submitted>
  <study_first_submitted_qc>August 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Reproductive Age</keyword>
  <keyword>poor ovarian response</keyword>
  <keyword>Mitochondrial dysfunction</keyword>
  <keyword>Mitochondrial nutrients</keyword>
  <keyword>Coenzyme Q10</keyword>
  <keyword>Electron transfer chain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

